Clostridium botulinum serotype a neurotoxin (bont/a) sequence variants
AssigneeAbbVie Inc.
InventorsRobert R. KEHRER, Jared WIG, Hui XIANG, Phillip P. NGUYEN, Hemant A. PATEL, Connie J. NG, Cortnie M. GUERRERO
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT/A) complex comprising a 150 kDa BoNT/A. Said 150 kDa BoNT/A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT/A sequence variant species with a C-terminal truncated light chain.
Claims34
A composition comprising a 900 kDa Clostridium botulinum neurotoxin serotype A (BoNT/A) complex, wherein the 900 kDa BoNT/A complex comprises a 150 kDa BoNT/A that is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT/A sequence variant species with a C-terminal truncated light chain and a 150 kDa BoNT/A sequence variant species with a full-length light chain, wherein the C-terminal truncated light chain has an amino acid sequence set forth in SEQ ID NO:
- 4, and the full-length light chain has an amino acid sequence set forth in SEQ ID NO:
- 2, and wherein the abundance ratio of the 150 kDa BoNT/A sequence variant species with the C-terminal truncated light chain to the 150 kDa BoNT/A sequence variant species with the full-length light chain is less than 3.9.
A composition comprising a 900 kDa BoNT/A complex, wherein the 900 kDa BoNT/A complex comprises a 150 kDa BoNT/A that is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT/A sequence variant species with a C-terminal truncated light chain, wherein the C-terminal truncated light chain has an amino acid sequence set forth in SEQ ID NO:
- 4, and wherein the abundance percentage of the 150 kDa BoNT/A sequence variant species with the C-terminal truncated light chain in the plurality of 150 kDa BoNT/A sequence variant species is less than 79.5%.
A method of producing a composition comprising BoNT/A, said method comprising incubating a culture of Clostridium botulinum bacteria in a production fermentor in the presence of CO2 in the fermentor headspace overlay during the fermentation process.
A method substantially as described herein.
A composition substantially as described herein.
Dependencies are inferred from the claim text.